Crystal structures of salinosporamide A (NPI-0052) and B (NPI-0047) in complex with the 20S proteasome reveal important consequences of β-lactone ring opening and a mechanism for irreversible binding

被引:253
作者
Groll, M
Huber, R
Potts, BCM
机构
[1] Univ Munich, D-81377 Munich, Germany
[2] Nereus Pharmaceut Inc, San Diego, CA 92121 USA
[3] Max Planck Inst Biochem, D-82152 Martinsried, Germany
关键词
D O I
10.1021/ja058320b
中图分类号
O6 [化学];
学科分类号
0703 ;
摘要
The crystal structures of the yeast 20S proteasome core particle (CP) in complex with Salinosporamides A (NPI-0052; 1) and B (4) were solved at < 3 A resolution. Each ligand is covalently bound to Thr10(y) via an ester linkage to the carbonyl derived from the beta-lactone ring of the inhibitor. In the case of 1, nucleophilic addition to the beta-lactone ring is followed by addition of C-30 to the chloroethyl group, giving rise to a cyclic ether. The crystal structures were compared to that of the omuralide/CP structure solved previously, and the collective data provide new insights into the mechanism of inhibition and irreversible binding of 1. Upon opening of the beta-lactone ring, C-30 assumes the position occupied by a water molecule in the unligated enzyme and hinders deacylation of the enzyme-ligand complex. Furthermore, the resulting protonation state of Thr1NH(2) deactivates the catalytic N-terminus.
引用
收藏
页码:5136 / 5141
页数:6
相关论文
共 29 条
[1]  
ADAMS J, 2004, PROTEASOME INHIBITOR
[2]   Approval summary for bortezomib for injection in the treatment of multiple myeloma [J].
Bross, PF ;
Kane, R ;
Farrell, AT ;
Abraham, S ;
Benson, K ;
Brower, ME ;
Bradley, S ;
Gobburu, JV ;
Goheer, A ;
Lee, SL ;
Leighton, J ;
Liang, CY ;
Lostritto, RT ;
McGuinn, WD ;
Morse, DE ;
Rahman, A ;
Rosario, LA ;
Verbois, SL ;
Williams, G ;
Wang, YC ;
Pazdur, R .
CLINICAL CANCER RESEARCH, 2004, 10 (12) :3954-3964
[3]  
Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/s0907444998003254
[4]   GEOMETRICAL REACTION COORDINATES .2. NUCLEOPHILIC ADDITION TO A CARBONYL GROUP [J].
BURGI, HB ;
DUNITZ, JD ;
SHEFTER, E .
JOURNAL OF THE AMERICAN CHEMICAL SOCIETY, 1973, 95 (15) :5065-5067
[5]   A novel orally active proteasome inhibitor induces apoptosis in multiple myeloma cells with mechanisms distinct from Bortezomib [J].
Chauhan, D ;
Catley, L ;
Li, GL ;
Podar, K ;
Hideshima, T ;
Velankar, M ;
Mitsiades, C ;
Mitsiades, N ;
Yasui, H ;
Letai, A ;
Ovaa, H ;
Berkers, C ;
Nicholson, B ;
Chao, TH ;
Neuteboom, STC ;
Richardson, P ;
Palladino, MA ;
Anderson, KC .
CANCER CELL, 2005, 8 (05) :407-419
[6]  
Corey EJ, 1999, CHEM PHARM BULL, V47, P1
[7]   Conformational constraints for protein self-cleavage in the proteasome [J].
Ditzel, L ;
Huber, R ;
Mann, K ;
Heinemeyer, W ;
Wolf, DH ;
Groll, M .
JOURNAL OF MOLECULAR BIOLOGY, 1998, 279 (05) :1187-1191
[8]   An extensively modified version of MolScript that includes greatly enhanced coloring capabilities [J].
Esnouf, RM .
JOURNAL OF MOLECULAR GRAPHICS & MODELLING, 1997, 15 (02) :132-+
[9]   Salinosporamide A:: A highly cytotoxic proteasome inhibitor from a novel microbial source, a marine bacterium of the new genus Salinospora [J].
Feling, RH ;
Buchanan, GO ;
Mincer, TJ ;
Kauffman, CA ;
Jensen, PR ;
Fenical, W .
ANGEWANDTE CHEMIE-INTERNATIONAL EDITION, 2003, 42 (03) :355-+
[10]   INHIBITION OF PROTEASOME ACTIVITIES AND SUBUNIT-SPECIFIC AMINO-TERMINAL THREONINE MODIFICATION BY LACTACYSTIN [J].
FENTEANY, G ;
STANDAERT, RF ;
LANE, WS ;
CHOI, S ;
COREY, EJ ;
SCHREIBER, SL .
SCIENCE, 1995, 268 (5211) :726-731